Trump's week in review: FDA update angers pro-lifers; Trump Accounts created for 70M children
5. Trump admin faces pushback for delaying abortion pill study
In a court filing Wednesday, the U.S. Food and Drug Administration said its ongoing safety review of the abortion pill mifepristone, along with its review of the drug’s Risk Evaluation and Mitigation Strategy (REMS), would not be finished until March 2027.
REMS is the set of FDA safety rules governing how the drug is prescribed and dispensed. The filing said the agency has completed “an assessment of study feasibility,” but it estimated that data will not be available until December.
The FDA filed the update by a deadline the court set in the ongoing litigation over the pill for “providing the Court with the status of its review in terms of process and any updated timeframe for completion of the review.”
Pro-life groups criticized the delay. Susan B. Anthony Pro-Life America President Marjorie Dannenfelser said the FDA has been “promising this review” for 20 months and accused the agency of “trying to peddle fool’s gold.” She also said, “There is no indication that the agency has obtained commercially available data.”
Last December, pro-life activists accused the FDA of stalling the safety review after Bloomberg reported that former FDA Commissioner Marty Makary told agency officials to put the review off until after the midterm elections.
“The FDA says it won’t complete its abortion pill safety analysis until March 2027, with no deadline for taking action,” said Lila Rose, founder and president of Live Action, in a statement Thursday. “This delay is UNACCEPTABLE. Every day, women are put at risk, and preborn children are killed.”
Ryan Foley is a reporter for The Christian Post. He can be reached at: ryan.foley@christianpost.com
